New scan could sharpen view of head and neck cancers
NCT ID NCT05183048
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether a special tracer called 89Zr panitumumab, used with PET/MRI scans, can show head and neck tumors more clearly than the standard FDG tracer. Fourteen newly diagnosed patients scheduled for surgery will receive both scans. The results are for research only and will not change their treatment plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [89Zr]Panitumumab Tracer
- What this could lead to
- If successful, this could lead to a more accurate imaging method for head and neck cancers, helping surgeons plan better.
- What could go wrong
- This is a very early, small study (14 people) focused only on imaging, not treatment. The new tracer may not prove better than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UAB
RECRUITINGBirmingham, Alabama, 35249, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?